Chinese Journal of Tissue Engineering Research ›› 2012, Vol. 16 ›› Issue (18): 3236-3240.doi: 10.3969/j.issn.1673-8225.2012.18.002

Previous Articles     Next Articles

Comparison of the incidence of infection and acute rejection in different anti-rejection treatment after renal transplantation

Huang Xiao-wei1, Liu Zhou2, Xie Min-yan1   

  1. 1Department of Nephrology, Central Hospital of Guangzhou Panyu District, Guangzhou  511400, Guangdong Province, China; 2the 458 Hospital of Chinese PLA, Guangzhou  510602, Guangdong Province, China
  • Received:2011-11-28 Revised:2011-12-16 Online:2012-04-29 Published:2012-04-29
  • Contact: Liu Zhou, Doctor, Chief physician, the 458 Hospital of Chinese PLA, Guangzhou 510602, Guangdong Province, China
  • About author:Huang Xiao-wei★, Master, Attending physician, Central Hospital of Guangzhou Panyu District, Guangzhou 511400, Guangdong Province, China shavey@tom.com

PDF

491

Abstract:

BACKGROUND: At present, there is no unified opinion about which immunosuppressive agent (especially the antibodies) at the peri-operative period of renal transplantation can reduce the incidence of acute rejection and not increase the risk of serious infection of patients.
OBJECTIVE: To compare the differences of the infection and acute rejection rate in six different immunosuppressive induction therapies for 6 months after renal transplantation. 
METHODS: In this prospective cohort study, 113 patients who received allogeneic kidney transplantation were divided into methylprednisolone (MP) group (n=29), MP+anti-human T lymphocyte glubin (ALG) group (n=17), MP+anti-thymocyte globulin (ATG) group (n=8), MP+daclizumab group (n=12), MP+ATG+daclizumab group (n=30), MP+ALG+daclizumab group (n=17). All groups were followed by the cyclosporin+mycophenolate mofetil+prednisone triple maintenance therapy after induced with immunosuppression treatment.
RESULTS AND CONCLUSIONS: ①The incidence of infection was lowest in MP+ATG group and highest in MP+ALG group. There was no significant difference among the groups. ②The incidence of acute rejection was highest in MP group and lowest in MP+ATG+daclizumab group. And the incidence of acute rejection in MP group was significantly higher than that in the MP+ATG+daclizumab group and MP+ALG+daclizumab group (P < 0.05). It is concluded that the incidence of acute rejection was lower in patients receiving combination induction of immunosuppressive therapy with both monoclonal and polyclonal antibodies, and the incidence of infection was not increased compared to treatment with MP, monoclonal or polyclonal antibody alone.

CLC Number: